by GOAI

由GOAI生成

Share To

分享到

Pfizer has entered into a licensing agreement with Novavax valued at $530 million. The deal grants Pfizer the rights to incorporate Novavax’s proprietary adjuvant, Matrix-M, into its vaccines targeting two specific disease areas. This collaboration marks a significant step in vaccine development for both companies..

辉瑞与诺瓦瓦克斯达成了一项价值5.3亿美元的许可协议。该协议授予辉瑞将其专有的佐剂Matrix-M纳入针对两个特定疾病领域的疫苗中的权利。这次合作标志着两家公司在疫苗开发方面迈出了重要的一步。

Under the terms of the agreement, Pfizer will utilize Matrix-M, an adjuvant designed to enhance immune responses and improve vaccine efficacy. The partnership aims to leverage this technology across multiple vaccine platforms. Details regarding the specific diseases targeted by this collaboration have not been disclosed..

根据协议条款，辉瑞将使用旨在增强免疫反应和提高疫苗效力的佐剂Matrix-N。该合作旨在多个疫苗平台上利用这项技术。关于此次合作针对的具体疾病细节尚未披露。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

For any suggestion and feedback, please contact us.

如果有任何建议和反馈，请联系我们。

Date: January 21, 2026

日期：2026年1月21日

Related posts:

相关文章：

Biopharmaceutical Companies Employ Patent Analysis: Active Ingredients, Formulations, and Manufacturing Processes Targeted for Freedom to Operate.

生物制药公司采用专利分析：针对活性成分、配方和生产工艺进行操作自由度分析。

Study Finds Link Between High Incarceration Rates and Increased Mortality Risks in Communities

研究发现高监禁率与社区死亡风险增加之间存在联系

Researchers Develop Method to Convert Shrimp Shell Waste into Biodegradable Packaging and Medical Products

研究人员开发出将虾壳废料转化为可生物降解包装和医疗产品的方法

Study Finds Community Pharmacists See Themselves as Key Players in Smoking Cessation Efforts but Face Barriers

研究发现，社区药剂师认为自己是戒烟工作的重要参与者，但面临障碍

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 版权所有。与我们合作：

[email protected]

电子邮件地址

Author

作者

GOAI

GOAI

Related Post

相关文章

News Flash

新闻快讯

Alan Balch Highlights Patient Struggles with Premiums and Health Savings Accounts in Insurance Navigation

艾伦·巴尔奇在保险导航中强调患者在保费和健康储蓄账户方面的挣扎。

2026-01-21

2026年1月21日